CSIMarket Company Name, Ticker, Industry, else..
 
Fractyl Health Inc   (NASDAQ: GUTS)
 
Price: $0.6431 $0.00 0.484%
Day's High: $0.6687999963760376 Week Perf: -6.39 %
Day's Low: $ 0.64 30 Day Perf: -8.39 %
Volume (M): 657,812 52 Wk High: $ 2.44
Volume (M$): $ 0 52 Wk Avg: $1.02
Open: $0.67 52 Wk Low: $0.38



 Market Capitalization (Millions $) 102
 Shares Outstanding (Millions) 159
 Employees 100
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -106
 Cash Flow (TTM) (Millions $) 37
 Capital Exp. (TTM) (Millions $) 0

Business Description


Fractyl Health, Inc. and its subsidiaries prepare consolidated financial statements in accordance with U.S. GAAP. The company operates in an industry characterized by high uncertainty and risk. Fractyl Health owns trademarks including REVITA and REJUVA and conducts internal research and market analysis to support its business operations.


   Company Address: 3 Van de Graaff Drive Burlington 1803 MA
   Company Phone Number: 902-8800    Stock Exchange / Ticker: NASDAQ GUTS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

A New Dawn for Diabetes Fractyl Unveils Promising Gene Therapy with Long-Lasting Benefits,

Published Sun, May 18 2025 11:09 AM UTC

Impending Revolution in Diabetes Treatment: Fractyl Health s Novel Gene Therapy Paves Path for Sustainable Metabolic Management In an era where the landscape of diabetes management is rapidly evolving, Fractyl Health, Inc. (NASDAQ: GUTS), a pioneer in the field of biotechnology, has recently revealed promising preclinical data surrounding its innovative Rejuva Smart GLP-1 p...
Clinical Study

In a bold stride towards addressing the dual challenges of obesity and metabolic health, Fracty...

Published Fri, Jan 31 2025 1:32 PM UTC

Title : Fractyl Health Turns Focus Toward Revita and Rejuva Therapies: Pioneering Solutions in Weight Maintenance and Pancreatic Health:In a bold stride towards addressing the dual challenges of obesity and metabolic health, Fractyl Health Inc. (NASDAQ: GUTS) has announced a strategic realignment of its research and development efforts. The company is enhancing its focus on ...
Clinical Study

Advancements in Local Gene Therapy Delivery An Exploration of RJVA-001 in Yucatan Pig Models

Published Thu, Dec 12 2024 12:00 PM UTC

: Fractyl Health has made significant strides in the field of gene therapy with the unveiling of promising preclinical data on RJVA-001, a novel Rejuva Smart GLP-1 pancreatic gene therapy. Presented at the World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC), this research highlights the safety and feasibility of local delivery methods in lar...
Clinical Study

Sustained Weight Loss Success One-Year Outcomes from Revita Clinical Studies for Type 2 Diabetes

Published Mon, Nov 4 2024 12:00 PM UTC

In an era where obesity and its associated comorbidities pose significant challenges to public health, innovative treatment modalities that facilitate weight loss and improve metabolic function are essential. At ObesityWeek 2024, Fractyl Health unveiled new insights from pooled data analysis of its Revita clinical studies that underscore the durability of weight loss mainten...
Clinical Study

Fractyl Health Reveals Breakthrough Results One-Year Weight Loss with Revita Procedure and Promising Gene Therapy Dat...

Published Thu, Aug 8 2024 12:01 PM UTC

Fractyl Health Unveils Promising Clinical Updates: Meaningful Weight Loss and Improved Body Composition Through Innovative TherapiesFractyl Health, a company at the forefront of innovative treatments for metabolic diseases, has announced encouraging results from its ongoing clinical programs. The press release reveals significant findings from a German real-world registry t...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 3
Working Capital Ratio 3.15
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.39 $
Revenues (TTM) -
Cash Flow (TTM) 0.23 $
Cash 0.3 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,056,500
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.